证券代码：600056 证券简称：中国医药 公告编号：临 2025-068 号 中国医药健康产业股份有限公司 关于子公司原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到欧洲药品质量管理局（EDQM） （以下简称"EDQM"）核准签发的克林霉素磷酸酯（以下简称"该药品"）《欧 洲药典适用性》证书(以下简称"CEP证书")。现将有关情况公告如下： 一、CEP证书基本信息 截至本公告披露日，EDQM证书数据库显示全球范围内批准的该药品CEP证书 有14个，其中有效的9个，无效的5个。 三、对上市公司的影响及风险提示 该药品 CEP 证书的获得，标志着公司克林霉素磷酸酯产品具备以化学原料药 形式进入欧洲及承认 CEP 证书的其他规范市场的资质，将有助于拓展国际化业务 及增强公司产品在全球市场的竞争力。 证书持有者及生产企业：天方药业有限公司 生产地址：河南省驻马店高新技术产业开发区建设大道 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-067 号 中国医药健康产业股份有限公司 关于子公司获得化学原料药上市申请批准通知书的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的富马酸伏诺拉生（以下简称"该药品"）《化 学原料药上市申请批准通知书》，现将有关情况公告如下： 一、通知书基本信息 化学原料药名称：富马酸伏诺拉生 （三）药品市场情况介绍 登记号：Y20230001371 化学原料药注册标准编号：YBY67962025 通知书编号：2025YS00695 包装规格：20kg/桶 生产企业：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品其他相关情况 （一）该药品主要用于治疗反流性食管炎。与适当的抗生素联用 ...

Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. has received the Certificate of Suitability (CEP) for Clindamycin Phosphate from the European Directorate for the Quality of Medicines (EDQM), which enhances the company's ability to enter European and other markets that recognize the CEP certificate [1] Group 1 - The CEP certificate signifies that the Clindamycin Phosphate product meets the standards for chemical raw materials, allowing the company to expand its international business [1] - Clindamycin Phosphate is a lincosamide antibiotic primarily used for treating infections caused by Gram-positive bacteria and anaerobic bacteria [1] - The approval of the CEP certificate is expected to strengthen the company's product competitiveness in the global market [1]

Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received approval from the National Medical Products Administration for the listing application of fumaric acid venlafaxine, which is primarily used to treat gastroesophageal reflux disease and eradicate Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical's approval for fumaric acid venlafaxine indicates that the raw material meets domestic drug registration requirements and has been approved for use in domestic formulations [1] - The approval of this raw material will further solidify the company's integrated development strategy of raw materials and formulations [1] - This development will expand the company's product range and accumulate valuable experience for future raw material drug applications [1]

Core Viewpoint - China Pharmaceutical announced that its wholly-owned subsidiary Tianfang Pharmaceutical received approval from the National Medical Products Administration for the listing application of fumaric acid volnorelaxin, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical has received the approval notice for fumaric acid volnorelaxin, indicating a significant advancement in its product pipeline [1] - The drug is intended for the treatment of gastroesophageal reflux disease and is used alongside antibiotics to eliminate Helicobacter pylori [1] - Additionally, Tianfang Pharmaceutical has obtained the European Pharmacopoeia suitability certificate for clindamycin phosphate, which is an antibiotic used for Gram-positive and anaerobic bacterial infections [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the market application of fumaric acid volnorasone, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical's approval for fumaric acid volnorasone indicates that the raw material meets domestic drug registration requirements and has been approved for use in domestic formulations [1] - The approval of this raw material will further solidify the company's integrated development strategy of raw materials and formulations [1] - This development will expand the company's product range and accumulate valuable experience for future raw material drug applications [1]

Core Viewpoint - China Pharmaceutical (600056) announced the approval of its subsidiary Tianfang Pharmaceutical's application for the active pharmaceutical ingredient Fumaric Acid Venlorasine by the National Medical Products Administration, indicating a significant advancement in its product pipeline [1] Group 1: Product Approvals - Tianfang Pharmaceutical received the approval notice for Fumaric Acid Venlorasine, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The company also obtained the European Pharmacopoeia suitability certificate for Clindamycin Phosphate, an antibiotic used for Gram-positive and anaerobic bacterial infections, from the European Medicines Agency [1]

Group 1 - The core point of the article is that Tianfang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of China National Pharmaceutical Group Corporation, has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnoreline [1] - The drug is primarily used for the treatment of gastroesophageal reflux disease and the eradication of Helicobacter pylori [1] - As of the date of the announcement, the total investment in the research and development of the raw materials and formulations for this project is approximately 11.36 million yuan [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Vonoprazan, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] Group 1 - The drug Fumaric Acid Vonoprazan has been approved for marketing, indicating a significant development for the company [1] - The approval is expected to enhance the company's product portfolio in the gastrointestinal treatment sector [1] - The drug's indication for use in combination with antibiotics highlights its potential in addressing common gastrointestinal infections [1]

Core Insights - The event highlighted the "2024 Annual Top 100 Enterprises in China's Pharmaceutical Industry," where Huabang Health (002004) was recognized as a leading pharmaceutical company again [1] - The ranking reflects the company's strong innovation drive and professional promotion capabilities within the pharmaceutical industry [1] Company Performance - Huabang Health has consistently focused on the health industry, enhancing its R&D investment, product quality control, and market channel expansion [1] - The company has improved its ranking since first being listed in 2020, showcasing its robust overall strength and industry leadership [1] Financial and Operational Highlights - In 2024, Huabang Health's medical business revenue showed steady growth, with bed utilization rates also improving [1] - The company placed significant emphasis on pharmaceutical R&D, achieving several milestones: four formulation products received market approval, one formulation product passed consistency evaluation, six raw material drug varieties and pharmaceutical excipients obtained A certification, and five raw material drug varieties received international certification [1] Product Development - Huabang Health is actively expanding into the dermatological product sector, launching two new functional skincare products to enhance its skin health product matrix [1] - The company aims to develop a comprehensive industry chain that integrates raw materials, formulations, functional skincare products, skin health management, and medical services [1]